X-Received: by 10.224.88.200 with SMTP id b8mr24684786qam.8.1366804335356; Wed, 24 Apr 2013 04:52:15 -0700 (PDT) MIME-Version: 1.0 X-Received: by 10.49.64.196 with SMTP id q4mr395889qes.2.1366804335320; Wed, 24 Apr 2013 04:52:15 -0700 (PDT) Path: news.ccsf.jp!norn-news!news.heimat.gr.jp!goblin2!goblin.stu.neva.ru!cyclone01.ams2.highwinds-media.com!voer-me.highwinds-media.com!npeer01.iad.highwinds-media.com!news.highwinds-media.com!feed-me.highwinds-media.com!gp5no2228087qab.0!news-out.google.com!ef9ni12521qab.0!nntp.google.com!gp5no5588480qab.0!postnews.google.com!12g2000vba.googlegroups.com!not-for-mail Newsgroups: fj.sci.medical Date: Wed, 24 Apr 2013 04:52:15 -0700 (PDT) Complaints-To: groups-abuse@google.com Injection-Info: 12g2000vba.googlegroups.com; posting-host=91.178.124.150; posting-account=jR3pwAkAAABfF7uqn-zMzWqez-yhPWKE NNTP-Posting-Host: 91.178.124.150 User-Agent: G2/1.0 X-HTTP-UserAgent: Mozilla/5.0 (Windows NT 5.1) AppleWebKit/537.31 (KHTML, like Gecko) Chrome/26.0.1410.64 Safari/537.31,gzip(gfe) Message-ID: Subject: CODING FOR DISEASE: GENES AND CANCER (2013) From: SMW Injection-Date: Wed, 24 Apr 2013 11:52:15 +0000 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: quoted-printable X-Received-Bytes: 15366 Xref: news.ccsf.jp fj.sci.medical:716 CODING FOR DISEASE: GENES AND CANCER (2013) Author: Marc Lacroix (InTextoResearch, Baelen, Wallonia, Belgium) Nova Sciences Publishers ISBN: 978-1-62257-817-7 (also available as e-book - ISBN: 978-1-62618-780-1) https://www.novapublishers.com/catalog/product_info.php?products_id=3D41658 Book Description: Cancer is characterized by uncontrolled cell division and the potential of the cells to invade surrounding tissues and spread around the body. Most of these changes in cellular behavior are the result of alterations in the function or levels of the proteins that control these processes. And these alterations are, in turn, usually caused by modifications at the DNA level. Indeed, cancer is now recognized as being essentially a disease caused by mutation, or dysregulated expression, of genes. Of the estimated 30,000 genes in the human genome, currently more than 250 are known to play an important role in the development of cancer, either sporadic or familial. In some cases, their effects result from gene fusion, due to translocation for instance, or from amplification of a chromosomal region. During the last years, attention has largely shifted from the identification of rare high-risk genetic mutations to a hunt for lower risk gene polymorphisms, many of which are likely to be common within the population. Another increasingly investigated field is epigenetics, which relates to abnormal and prolonged changes in the mechanisms that alter gene expression and activity, without involving changes in genetic sequence. Table of Contents Preface Chapter 1: A Detailed List of Major Cancer Genes Chapter 2: Gene Fusions in Cancer Chapter 3: Gene Amplification in Cancer Chapter 4: Low Penetrance Sites in Cancer: Candidate Genes Chapter 5: Familial Cancer Syndromes Chapter 6: Epigenetics and Cancer The Author Born in 1963, Marc Lacroix has been working on breast cancer in several academic institutions and at InTextoResearch, an agency devoted to scientific information on cancer. He authored four books: =E2=80=9CTumor Suppressor Genes in Breast Cancer=E2=80=9D (2008), =E2=80=9C= Molecular Therapy of Breast Cancer: Classicism meets Modernity=E2=80=9D (2009), =E2=80=9CMicr= oRNAs in Breast Cancer=E2=80=9D (2010) and =E2=80=9CA Concise History of Breast Canc= er=E2=80=9D (2011 & 2013) http://en.wikipedia.org/wiki/Marc_Lacroix_(biochemist) Index Chapter 1 ABL1 (v-abl Abelson murine leukemia viral oncogene homolog 1) AKT1 (RAC-alpha serine/threonine-protein kinase) AKT2 (v-akt murine thymoma viral oncogene homolog 2) ALK (Anaplastic lymphoma receptor tyrosine kinase) APC (Adenomatous polyposis coli) ARID1A (AT rich interactive domain 1A) ARID1B (AT rich interactive domain 1B) ARID2 (AT rich interactive domain 2) ASXL1 (Additional sex combs like 1) ATM (Ataxia telangiectasia mutated) BAP1 (BRCA1 associated protein-1) BLM (Bloom syndrome, RecQ helicase-like) BMPR1A (Bone morphogenetic protein receptor, type IA) BRAF (v-raf murine sarcoma viral oncogene homolog B1) BRCA1 (Breast cancer 1, early onset) BRCA2 (Breast cancer 2, early onset) BRIP1 (BRCA1 interacting protein C-terminal helicase 1) BUB1B (Budding uninhibited by benzimidazoles 1 homolog beta) CASP8 (Caspase 8, apoptosis-related cysteine peptidase) CBFB (Core-binding factor, beta subunit) CBL (Cas-Br-M (murine) ecotropic retroviral transforming sequence) CDH1 (Cadherin 1, type 1, E-cadherin) CDK4 (Cyclin-dependent kinase 4) CDKN1B (Cyclin-dependent kinase inhibitor 1B) CDKN2A (Cyclin-dependent kinase inhibitor 2A) CEBPA (CCAAT/enhancer binding protein (C/EBP), alpha) CHEK2 (CHK2 checkpoint homolog) CTNNB1 (Catenin (cadherin-associated protein), beta 1, 88kDa) CYLD (Cylindromatosis) DDB2 (also known as XPE) (Damage-specific DNA binding protein 2) DNMT3A (DNA (cytosine-5-)-methyltransferase 3 alpha) EGFR (Epidermal growth factor receptor) ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog) ERCC2 (also known as XPD) (Excision repair cross-complementing rodent repair deficiency, complementation group 2) ERCC3 (also known as XPB) (Excision repair cross-complementing rodent repair deficiency, complementation group 3) ERCC4 (also known as XPF) (Excision repair cross-complementing rodent repair deficiency, complementation group 4) ERCC5 (also known as XPG) (Excision repair cross-complementing rodent repair deficiency, complementation group 5) EXT1 (Exostosin-1) EXT2 (Exostosin-2) EZH2 (Enhancer of zeste homolog 2) FAM123B (Family with sequence similarity 123B) Fanconi Anemia pathway FANCA (Fanconi anemia, complementation group A) FANCB (Fanconi anemia, complementation group B) FANCC (Fanconi anemia, complementation group C) FANCD1 (also known as BRCA2) (Fanconi anemia, complementation group D1) FANCD2 (Fanconi anemia, complementation group D2) FANCE (Fanconi anemia, complementation group E) FANCF (Fanconi anemia, complementation group F) FANCG (Fanconi anemia, complementation group G) FANCI (Fanconi anemia, complementation group I) FANCJ (also known as BRIP1) (Fanconi anemia, complementation group J) FANCL (Fanconi anemia, complementation group L) FANCM (Fanconi anemia, complementation group M) FBXW7 (F-box and WD repeat domain containing 7) FGFR3 (Fibroblast growth factor receptor 3) FH (Fumarate hydratase ) FLCN (Folliculin) FLT3 (Fms-related tyrosine kinase 3) FOXL2 (Forkhead box L2) GATA1 (GATA binding protein 1) GATA3 (GATA binding protein 3) GNAQ (Guanine nucleotide binding protein (G protein), q polypeptide) GNAS (GNAS complex locus) HNF1A (HNF1 homeobox A) HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog) IDH1 (Isocitrate dehydrogenase 1) IDH2 (Isocitrate dehydrogenase 2) JAK2 (Janus kinase 2) KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) KLF6 (Kruppel-like factor 6) KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) MAP2K4 (Mitogen-activated protein kinase kinase 4) MAP3K1 (Mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase) MAP3K13 (Mitogen-activated protein kinase kinase kinase 13) MEN1 (Multiple endocrine neoplasia I) MLH1 (MutL homolog 1, colon cancer, nonpolyposis type 2) MSH2 (MutS homolog 2, colon cancer, nonpolyposis type 1) MSH6 (MutS homolog 6) MPL (Myeloproliferative leukemia virus oncogene) MUTYH (MutY homolog) MYC (v-myc myelocytomatosis viral oncogene homolog) NCOR1 (Nuclear receptor corepressor 1) NF1 (Neurofibromin 1) & NF2 (Neurofibromin 2) NOTCH1 (Notch 1) NPM1 (Nucleophosmin 1) NRAS (Neuroblastoma RAS viral (v-ras) oncogene homolog) NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) PALB2 (also known as FANCN) (Fanconi anemia, complementation group N) PBRM1 (Polybromo 1) PDGFRA (Platelet-derived growth factor receptor, alpha polypeptide) PHOX2B (Paired-like homeobox 2b) PIK3CA (Phosphoinositide-3-kinase, catalytic, alpha polypeptide) PMS1 (PMS1 postmeiotic segregation increased 1) PMS2 (PMS2 postmeiotic segregation increased 2) POLH (also known as XPV) (Polymerase (DNA directed), eta) Polycomb group (PcG) proteins PPP2R1A (protein phosphatase 2, regulatory subunit A, =CE=B1) PRKAR1A (Protein kinase, cAMP-dependent, regulatory, type I, =CE=B1) PTCH1 (Patched 1) PTEN (Phosphatase and tensin homolog) PTPN11 (Protein tyrosine phosphatase, non-receptor type 11) RAD51C (RAD51 homolog C) RAD51C (also known as FANCO) (Fanconi anemia, complementation group O) RB1 (Retinoblastoma 1) RECQL4 (RecQ protein-like 4) RET (Ret proto-oncogene) RUNX1 (Runt-related transcription factor 1) SDHA (Succinate dehydrogenase complex, subunit A, flavoprotein variant) SDHAF2 (Succinate dehydrogenase complex assembly factor 2) SDHB (Succinate dehydrogenase complex, subunit B, iron sulfur) SDHC (Succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa) SDHD (Succinate dehydrogenase complex, subunit D, integral membrane protein) SETD2 (SET domain containing 2) SF3B1 (Splicing factor 3b, subunit 1, 155kDa) SMAD4 (SMAD family member 4) SMO (Smoothened homolog) SOCS1 (Suppressor of cytokine signaling 1) STK11 (Serine/threonine kinase 11) SUFU (Suppressor of fused homolog) SWI/SNF complex components SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4) SMARCB1 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1) are the most frequently mutated. TBX3 (T-box 3) TET2 (Tet (ten-eleven-translocation) oncogene family member 2) TMEM127 (Transmembrane protein 127) TNFAIP3 (Tumor necrosis factor, alpha-induced protein 3) TP53 (Tumor protein p53) TSC1 (Tuberous sclerosis 1) & TSC2 (Tuberous sclerosis 2) TSHR (Thyroid stimulating hormone receptor) XPA (Xeroderma pigmentosum, complementation group A) XPC (Xeroderma pigmentosum, complementation group C) WRN (Werner syndrome, RecQ helicase-like) WT1 (Wilms tumor 1) Chapter 2 Balanced translocations and gene fusions Deletions and gene fusions Dicentric aberrations and gene fusions Insertions and gene fusions Inversions and gene fusions Non-reciprocal translocations and gene fusions Ring chromosome and gene fusions Chapter 3 AKT2 (V-akt murine thymoma viral oncogene homolog 2) AR (Androgen receptor) ARPC1A (Actin related protein 2/3 complex, subunit 1A, 41kDa) AURKA (Aurora kinase A) BCL2L2 (BCL2-like 2) CACNA1E (Calcium channel, voltage-dependent, R type, alpha 1E subunit) CCND1 (Cyclin D1) CCNE1 (Cyclin E1) CDK4 (Cyclin-dependent kinase 4) CDK6 (Cyclin-dependent kinase 6) CHD1L (Chromodomain helicase DNA binding protein 1-like) CKS1B (CDC28 protein kinase regulatory subunit 1B) DCUN1D1 (DCN1, defective in cullin neddylation 1, domain containing 1) DYRK2 (Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2) E2F3 (E2F transcription factor 3) EGFR (Epidermal growth factor receptor) EIF5A2 (Eukaryotic translation initiation factor 5A2) ERBB2 (V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog) FADD (Fas (TNFRSF6)-associated via death domain) FGFR1 (Fibroblast growth factor receptor 1) GATA6 (GATA binding protein 6) GPC5 (Glypican 5) GRB7 (Growth factor receptor-bound protein 7) JUN (Jun proto-oncogene) KIT (V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) MAP3K5 (Mitogen-activated protein kinase kinase kinase 5) MDM2 (Mdm2, p53 E3 ubiquitin protein ligase homolog) MDM4 (Mdm4 p53 binding protein homolog) MED29 (Mediator complex subunit 29) MET (Met proto-oncogene) MITF (Microphthalmia-associated transcription factor) MTDH (Metadherin) MYC (V-myc myelocytomatosis viral oncogene homolog) MYCL1 (V-myc myelocytomatosis viral oncogene homolog 1, lung carcinoma derived) MYCN (V-myc myelocytomatosis viral related oncogene, neuroblastoma derived) NCOA3 (Nuclear receptor coactivator 3) NKX2-1 (NK2 homeobox 1) NKX2-8 (NK2 homeobox 8) PAK1 (P21 protein (Cdc42/Rac)-activated kinase 1) PAX9 (Paired box 9) PIK3CA (Phosphoinositide-3-kinase alpha polypeptide) PPM1D (Protein phosphatase, Mg2+/Mn2+ dependent, 1D) PRKCI (Protein kinase C, iota) RAB25 (RAB25, member RAS oncogene family) REL (V-rel reticuloendotheliosis viral oncogene homolog) RPS6KB1 (Ribosomal protein S6 kinase, 70kDa, polypeptide 1) SKP2 (S-phase kinase-associated protein 2, E3 ubiquitin protein ligase) SMURF1 (SMAD specific E3 ubiquitin protein ligase 1) STARD3 (StAR-related lipid transfer (START) domain containing 3) TSPAN31 (Tetraspanin 31) WHSC1L1 (Wolf-Hirschhorn syndrome candidate 1-like 1) YWHAB (Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta polypeptide) YWHAQ (Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta polypeptide) YWHAZ (Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide) ZNF217 (Zinc finger protein 217) ZNF639 (Zinc finger protein 639) Chapter 4 GWAS in bladder cancer GWAS in breast cancer (BC) GWAS in colorectal cancer (CRC) GWAS in lung cancer (LC) GWAS in cancer types other than bladder, breast, colorectal, esophageal, lung, prostate, and upper aerodigestive GWAS in prostate cancer (PC) GWAS in upper aerodigestive and esophageal cancers Chapter 5 Ataxia Telangiectasia Basal Cell Nevus Syndrome Beckwith=E2=80=93Wiedemann Syndrome Birt=E2=80=93Hogg=E2=80=93Dub=C3=A9 Syndrome Bloom Syndrome Carney Complex, Types I and II Cowden Syndrome Dyskeratosis Congenita Familial Adenomatous Polyposis Familial platelet disorder with predisposition to acute myelogenous leukemia Fanconi Anemia Hereditary Breast/Ovarian Cancer Hereditary Diffuse Gastric Cancer Hereditary Leiomyomatosis and Renal Cell Cancer Hereditary Multiple Exostosis Hereditary Nonpolyposis Colon Cancer Hereditary Papillary Renal Cell Carcinoma Hereditary paraganglioma-pheochromocytoma syndrome Li=E2=80=93Fraumeni Syndrome, including Li-Fraumeni-Like Syndrome Multiple Endocrine Neoplasia Type 1 Multiple Endocrine Neoplasia Type 2A, 2B MYH-Associated Polyposis Neurofibromatosis Type 1 Neurofibromatosis Type 2 Nijmegen Breakage Syndrome Peutz=E2=80=93Jeghers Syndrome Polyposis, Familial Juvenile Retinoblastoma, Hereditary Rhabdoid Tumor Predisposition Syndrome Rothmund=E2=80=93Thomson Syndrome Shwachman-Bodian-Diamond Syndrome Simpson=E2=80=93Golabi=E2=80=93Behmel Syndrome Tuberous Sclerosis Complex Variegated Aneuploidy, Mosaic Von Hippel=E2=80=93Lindau Syndrome Werner Syndrome Wilms Tumor, Familial Xeroderma Pigmentosum Chapter 6 Cancer mutations in histone genes Chromatin remodelers DNA Hydroxy-Methylation and Its Oxidation Derivatives DNA Methylation: Histone acetylation Histone acetylation readers Histone demethylation Histone desacetylation Histone methylation Histone methylation readers Histone modifications Histone phosphorylation Noncoding RNAs